ASX:NEUPharmaceuticals
How Investors Are Reacting To Neuren Pharmaceuticals (ASX:NEU) Larger-Than-Expected Phelan-McDermid Syndrome Population Estimate
In June 2026, Mount Sinai’s Seaver Autism Center published research in Autism Research estimating Phelan-McDermid syndrome affects about 1 in 7,300 people, a much higher prevalence than earlier thought, in a study supported by CureSHANK and Neuren Pharmaceuticals.
This substantially larger patient population estimate highlights a potentially wider addressable market for ongoing precision medicine trials and future therapies targeting Phelan-McDermid syndrome.
We’ll now examine how this...